CMS – Page 58 – medicarereport.org

A trusted source for Medicare news and education from the AMAC Foundation.

The New Help for Medicare Beneficiaries with High Drug Costs That Few Seem to Know About

(By Juliette Cubanski and Tricia Neuman for the Kaiser Family Foundation Published: Dec 12, 2023) The Inflation Reduction Act of

Eileen Cook December 14, 2023December 14, 2023 CMS, Healthcare Costs, Inflation Reduction Act of 2022, medicare, Medicare Advantage, Medicare Part D, Older Adults, Out-of-pocket prescription costs

CMS Health Care Finance Health Care Redesign Health Insurance Legislative Update Medical Debt Medicare - General Part D/Prescription Drugs Price Transparency

3 Inflation Reduction Act Medicare changes taking effect in 2024

(By Rylee Wilson for Becker’s Hospital Review ) The federal government will cap drug copays and premiums for Medicare beneficiaries

Eileen Cook December 12, 2023December 12, 2023 CMS, Drug price Transparency, Healthcare Costs, Inflation Reduction Act of 2022, medicare, Medicare Insulin Cost-sharing, Medicare Part D, Older Adults

CMS Health Care Finance Medicare Advantage

Is the Medicare Advantage ‘gold rush’ over?

(By Rylee Wilson for Becker’s Hospital Review ) The Medicare Advantage gold rush is slowing down, Wall Street Journal columnist

Eileen Cook December 7, 2023December 7, 2023 CMS, medicare, Medicare Advantage, Medicare Part D, Mergers, Older Adults

CMS DHS -OIG Health Care Finance Medicare Advantage

10 payers audited for Medicare Advantage overpayments in 2023

(By Rylee Wilson for Becker’s Hospital Review ) OIG audits found over $213 million in estimated Medicare Advantage overpayments in

Eileen Cook December 5, 2023December 5, 2023 CMS, DHS -Office of Inspector General, Healthcare Costs, Healthcare Finance, Medicare Advantage, Medicare Advantage Audits, Medicare Advantage Overpayments

CMS Dental/Oral Health Health Care Finance Health Care Redesign Medicare - General

Recent Changes to Medicare Coverage of Dental Services from the 2023 and 2024 Medicare Physician Fee Schedule Final Rules

(By Meredith Freed, Tricia Neuman, and Juliette Cubanski for the Kaiser Family Foundation Published: Dec 01, 2023) Medicare does not

Eileen Cook December 4, 2023December 4, 2023 CMS, dental health, Healthcare Costs, Healthcare redesign, medicare, Older Adults

DHS -OIG Medicare Advantage

OIG: Centene subsidiary received estimated $5.1M in Medicare Advantage overpayments

(By Rylee Wilson for Becker’s Hospital Review ) SelectCare of Texas, a Centene subsidiary, received an estimated $5.1 million in

Eileen Cook December 4, 2023December 4, 2023 CMS, DHS -Office of Inspector General, Medicare Advantage, Medicare Advantage Overpayments

CMS DHS -OIG Medicaid

OIG: 14 states paid managed care organizations $249M for deceased Medicaid enrollees

(By Rylee Wilson for Becker’s Hospital Review ) Fourteen states gave managed care organizations payments for Medicaid enrollees for months

Eileen Cook December 1, 2023December 1, 2023 CMS, Deceased Medicaid Enrollees, DHS-OIG, HHS Inspector General’s Office Audit, Improper Payments, Medicaid, Medicaid Managed Care

CMS Medicare - General Medicare Advantage Part D/Prescription Drugs

Uncle Sam Wants You … to Help Stop Insurers’ Bogus Medicare Advantage Sales Tactics

(By Susan Jaffe for KFF Health News) After an unprecedented crackdown on misleading advertising claims by insurers selling private Medicare

Eileen Cook November 30, 2023November 30, 2023 CMS, medicare, Medicare Advantage, Medicare Advantage Ads, Medicare Part D, Older Adults

Emerging Health Issues Health Care - General Health Insurance Medicare Advantage Prior Authorization

Bipartisan anger over Medicare Advantage denials on the rise

(By Rylee Wilson for Becker’s Hospital Review ) Concerns about Medicare Advantage denials are on the rise in Washington, Politico

Eileen Cook November 28, 2023November 28, 2023 Bipartisan Support, CMS, Medicare Advantage, Medicare Advantage claims denials, Medicare Advantage Prior Authorization

Alzheimer’s/Dementia FDA Medicare - General Part D/Prescription Drugs

Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect

(By Madhav Thambisetty for ST A T) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision

Eileen Cook November 28, 2023November 28, 2023 Aducanumab, Alzheimer’s Disease, ARIA, CMS, Dementia, Donanemab, FDA, Lecanemab Drug, medicare, Medicare Part D, Older Adults